[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2020011619A - Urolitina como mejorador inmunitario. - Google Patents

Urolitina como mejorador inmunitario.

Info

Publication number
MX2020011619A
MX2020011619A MX2020011619A MX2020011619A MX2020011619A MX 2020011619 A MX2020011619 A MX 2020011619A MX 2020011619 A MX2020011619 A MX 2020011619A MX 2020011619 A MX2020011619 A MX 2020011619A MX 2020011619 A MX2020011619 A MX 2020011619A
Authority
MX
Mexico
Prior art keywords
stem cell
urolithins
immune
relates
urolithin
Prior art date
Application number
MX2020011619A
Other languages
English (en)
Inventor
Christopher Rinsch
Anurag Singh
Davide D''amico
Pénélope Andreux
William Blanco-Bose
Original Assignee
Amazentis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1807051.6A external-priority patent/GB201807051D0/en
Priority claimed from GBGB1807819.6A external-priority patent/GB201807819D0/en
Application filed by Amazentis Sa filed Critical Amazentis Sa
Publication of MX2020011619A publication Critical patent/MX2020011619A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a compuestos para usar a fin de generar una respuesta inmunitaria a un antígeno y/o mejorar, modular o aumentar una respuesta inmunitaria a un antígeno. Particularmente el uso de urolitinas. La invención también se refiere a mejoradores inmunitarios que comprenden urolitinas, métodos para usar tales mejoradores inmunitarios y procesos para la preparación de tales mejoradores inmunitarios. La invención también se refiere al uso de urolitinas en métodos para modular la función de las células madre, por ejemplo, mejorar la cantidad de células madre, promover la regeneración de las células madre y promover la diferenciación de las células madre.
MX2020011619A 2018-04-30 2019-04-30 Urolitina como mejorador inmunitario. MX2020011619A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1807051.6A GB201807051D0 (en) 2018-04-30 2018-04-30 Biological enhancer
GBGB1807819.6A GB201807819D0 (en) 2018-05-14 2018-05-14 Biological enhancer
PCT/EP2019/061093 WO2019211294A1 (en) 2018-04-30 2019-04-30 Urolithin a as immune enhancer

Publications (1)

Publication Number Publication Date
MX2020011619A true MX2020011619A (es) 2021-01-15

Family

ID=66379918

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020011619A MX2020011619A (es) 2018-04-30 2019-04-30 Urolitina como mejorador inmunitario.
MX2023013675A MX2023013675A (es) 2018-04-30 2020-10-30 Urolitina como mejorador inmunitario.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023013675A MX2023013675A (es) 2018-04-30 2020-10-30 Urolitina como mejorador inmunitario.

Country Status (7)

Country Link
US (3) US10792276B2 (es)
EP (1) EP3787615A1 (es)
JP (1) JP7557374B2 (es)
CN (1) CN112512517A (es)
BR (1) BR112020022159A2 (es)
MX (2) MX2020011619A (es)
WO (1) WO2019211294A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7557374B2 (ja) 2018-04-30 2024-09-27 アマゼンティス エスアー 免疫増強剤としてのウロリチンａ
GB201912107D0 (en) * 2019-08-22 2019-10-09 Amazentis Sa Combination
US20240000747A1 (en) * 2020-11-26 2024-01-04 Daicel Corporation Sirtuin 6 activator
JP2024503753A (ja) 2021-01-27 2024-01-26 ヴァンドリア エスアー ウロリチン誘導体及びその使用方法
BR112023022224A2 (pt) * 2021-05-05 2024-02-06 Ludwig Inst For Cancer Res Ltd Urolitina para aumentar função de célula-tronco
CN113813255B (zh) * 2021-10-20 2023-09-01 山东大学 尿石素a及其衍生物在肿瘤免疫治疗的应用
GB202219317D0 (en) * 2022-12-20 2023-02-01 Amazentis Sa Methods for improving mitophagy in subjects

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183282B2 (en) 2006-04-26 2012-05-22 The Regents Of The University Of California Therapeutic uses of urolithins
MX2020008468A (es) * 2012-06-27 2022-06-14 Amazentis Sa Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
EP3087065B1 (en) 2013-12-23 2020-01-22 Amazentis SA Synthesis of urolithins
US20170367390A1 (en) * 2014-12-19 2017-12-28 Halo Life Science, Llc Use of ellagic acid dihydrate in food products and nutraceuticals
US20170304263A1 (en) * 2016-04-20 2017-10-26 John Michael Pezzuto Antioxidative stress compositions, methods of preparing and uses thereof
JP7557374B2 (ja) 2018-04-30 2024-09-27 アマゼンティス エスアー 免疫増強剤としてのウロリチンａ

Also Published As

Publication number Publication date
JP7557374B2 (ja) 2024-09-27
US20230097072A1 (en) 2023-03-30
US20190328703A1 (en) 2019-10-31
MX2023013675A (es) 2024-01-08
CN112512517A (zh) 2021-03-16
US11426380B2 (en) 2022-08-30
US10792276B2 (en) 2020-10-06
BR112020022159A2 (pt) 2021-01-26
US12109190B2 (en) 2024-10-08
WO2019211294A1 (en) 2019-11-07
EP3787615A1 (en) 2021-03-10
JP2021522296A (ja) 2021-08-30
US20210085642A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
MX2023013675A (es) Urolitina como mejorador inmunitario.
PH12018502348A1 (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
MX2019002946A (es) Anticuerpos anti-pd-1 y sus usos.
PH12019502331A1 (en) Treatment of asthma with anti-tslp antibody
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
GEP20227419B (en) Pd-1-binding molecules and methods of use thereof
EA201992469A1 (ru) Антигенспецифические иммунные эффекторные клетки
SG10201914126RA (en) Anti-ox40 antibodies and their uses
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
ZA202208710B (en) Anti-vegf protein compositions and methods for producing the same
PH12020550025A1 (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
WO2015132675A3 (en) Methods and compositions for modifying the immune response
SG10201801219VA (en) Anti-HER2 Antibodies
PH12017500722A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
PH12019502075A1 (en) A liquid formulation of anti-tnf alpha antibody
MX2019008648A (es) Anticuerpos anti-envoltura herv-k y usos de los mismos.
MX2023014154A (es) Anticuerpos anti-ccr8.
AU2017261305A8 (en) DNA monoclonal antibodies targeting influenza virus
MX2021015473A (es) Nuevo anticuerpo específico para cthrc1 y su uso.
MX2022005215A (es) Metodos de tratamiento que usan un modulador de la diana mecanicista del complejo 1 de rapamicina (mtorc1).